Changes in Ciliary Body Thickness in Patients With Diabetic Macular Edema After Vitrectomy

Seoul National University Hospital82 enrolled

Overview

The purpose of this study is to determine whether ciliary body thickness increased in the presence of diabetic macular edema and whether it changed after pars plana vitrectomy.

A diabetic macular edema group consisted of diabetic patients who underwent PPV for diffuse diabetic macular edema. A epiretinal membrane group, a surgical control group, consisted of non-diabetic patients with epiretinal membrane who underwent pars plana vitrectomy. A healthy control was also included for the comparison of preoperative ciliary body thickness. Ciliary body thickness was measured using ultrasound biomicroscopy, and central macular thickness was determined using optical coherence tomography. The visual outcome, ciliary body thickness, and central macular thickness were compared between groups before and 1, 2, and 4 months after pars plana vitrectomy and the correlations between the central macular thickness and ciliary body thickness and best corrected visual acuity were determined.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

Conditions

Diabetic Macular Edema

Interventions

Pars Plana VitrectomyPROCEDURE

25-gauge three-port pars plana vitrectomy

Eligibility

Sex: ALLMin age: 20 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria for diabetic macular edema group: * Diabetic macular edema with preoperative central macular thickness \> 300 μm on optical coherence tomography * Macular edema that was not associated with an epiretinal membrane or traction membrane * No combined traction retinal detachment or vitreous hemorrhage * No signs of ocular inflammatory disease on preoperative examination * Phakic eye * An axial length between 22.0 mm and 25.0 mm Exclusion Criteria for diabetic macular edema group: * Patients with uveitis, inflammatory connective tissue disorders or a history of previous ocular surgery * Long-term application of topical medication, a history of intravitreal steroid or anti-VEGF injection within 3 months before vitrectomy Inclusion Criteria for epiretinal membrane group: * Non-diabetic patients with an epiretinal membrane who were scheduled for vitrectomy * No ocular or systemic disease other than epiretinal membrane Inclusion Criteria for healthy group: * No diabetes * No ocular disease other than cataract

Locations (1)

Department of Ophthalmology, Seoul National University Hospital

Seoul, South Korea

Outcomes

Primary Outcomes

ciliary body thickness

ciliary body thickness was determined using ultrasound biomicroscopy

Time frame: up to four months after surgery

Secondary Outcomes

central macular thickness

central macular thickness was determined using optical coherence tomography

Time frame: up to four months after surgery

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.